Pneumothorax Treatment Market Analysis

End-user (Hospital, Clinics, Ambulatory Distribution Channel)

The hospital segment in pneumothorax treatment market is estimated to gain a significant share of about ~44% in the year 2036. The availability of hospitals throughout the world and the availability of rapid and simple treatments for pneumothorax infections are both factors contributing to the segment's growth, which is anticipated to fuel market expansion. For reference, the number of hospitals worldwide as of 2021 is estimated to be 165,000. Hospitals are the primary end users in the pneumothorax treatment market, offering therapy, post-treatment care, and assistance for diagnostics to patients infected with pneumothorax.

Type (Primary Spontaneous, Secondary Spontaneous, Latrogenic, Injury Related, Catamenial)

The secondary spontaneous pneumothorax segment in pneumothorax treatment market is estimated to gain the largest revenue share of about ~30% in the year 2036. The segment growth can be attributed to the growing prevalence of persistent lung diseases consisting of bronchial asthma, interstitial lung disease (ILD), cystic fibrosis, or lung cancers. A secondary spontaneous pneumothorax refers to a spontaneous pneumothorax in a patient with preexisting persistent lung ailments. Studies show that around 545 million people worldwide, or 7·4% of the total population, suffer from a chronic respiratory ailment.  Furthermore, because of the growing older populations, there can be a rise in the incidence of secondary spontaneous pneumothorax (SSP) because it typically happens in older populations, mostly with accompanying health conditions. Thus, the market segment is expected to hold the largest market share in the forecast period.